

Please try another search
For the three months ended 31 March 2022, Voyager Therapeutics Inc revenues decreased 90% to $658K. Net loss decreased 2% to $21.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development decrease of 35% to $13.5M (expense), General and administrative decrease of 18% to $6.1M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0.66 | 28.07 | 1.48 | 1.36 |
Gross Profit | ||||
Operating Income | -21.35 | 5.7 | -25.15 | -28.59 |
Net Income | -21.32 | 5.71 | -25.14 | -30.12 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 224.18 | 193.85 | 184.77 | 208.73 |
Total Liabilities | 148.25 | 98.8 | 97.35 | 98.19 |
Total Equity | 75.93 | 95.06 | 87.42 | 110.54 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 34.43 | -53.52 | -64.72 | -44.01 |
Cash From Investing Activities | -20 | 65.91 | 71.37 | 57.03 |
Cash From Financing Activities | 0.01 | 0.61 | 0.39 | 0.39 |
Net Change in Cash | 14.44 | 12.99 | 7.04 | 13.4 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review